Orforglipron Weight Loss Pill discovered by “Eli Lilly and Company“, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Lilly comes into limelight with new experimental pill which worked effectively as like as Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

“Orforglipron” pill, raised hopes of an effectiveness and easy-to-use treatment, which is set to now reaching a market dominated by weight-loss injections.

The trial, which included 559 obese people with type 2 diabetes from the U.S., China, India, Japan and Mexico, also found that the daily pill lowered blood sugar levels, in some cases bringing them below the formal threshold for diabetes.

The 40-week trial showed that taking a daily pill of 3mg, 12mg or 36mg reduced blood sugar by 1.2% to 1.5%. During the same period, participants saw an average weight loss of 4.5% on the 3mg pill, 5.8% on the 12mg pill and 7.6% on the 36mg pill. People who took a 36-milligram pill of orfoglipron lost an average of 7.3 kilograms (16 pounds) over nine months, according to results of a Phase 3 clinical trial reported Thursday by the drug’s maker, Eli Lilly.

The results will be presented at the American Diabetes Association meeting in June, after which they will be published in a peer-reviewed journal. The company said it would apply for approval to market the drug for weight management later this year and for type 2 diabetes next year.

David Ricks, chief executive of Eli Lilly, said: “As a convenient pill taken once daily, orfoglipron could provide a new option and, if approved, could be easily manufactured and launched on a large scale for use by people around the world.” In a statement accompanying the results, the company said the drug met expectations in terms of safety, tolerability, glucose control and weight loss.

Weight loss drugs have boomed in popularity, but health officials believe daily pill versions of the drug could allow more people to control their weight and blood sugar levels. In the UK, two-thirds of adults are either overweight or obese and more than 5 million people have type 2 diabetes.

Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said: “These are important results. Having new oral agents that lower glucose but also reduce weight more than existing diabetes treatments is important for the future of type 2 diabetes care. Of course, one caveat is that we don’t know the effects of this new therapy on cardiovascular outcomes, but that will be revealed in future trials.”

Lilly’s phase 3 trial showed that patients with type 2 diabetes lost 16 pounds, or about 8% of their body weight, over 40 weeks. This is better than Novo’s injectable drug Ozempic, where diabetics on the highest dose lost about 6% of their body weight. Lilly said weight loss had not stabilized by the time the study ended, suggesting patients could lose more weight. The pill lowered blood sugar levels by an average of 1.3%. Ozempic lowered blood sugar levels by 2.1%.

Ozempic, approved for diabetes in 2017, is designed to target an intestinal hormone called GLP-1. It competes with Lilly’s injectable tirzepatide — sold under the brand names Monjaro for obesity and Zepbound for weight loss — which mimics GLP-1 and another hormone called GIP, and has demonstrated a 22% weight loss reduction over 72 weeks.